Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

36.86 +0.50 (+1.38%)
Streaming Delayed Price Updated: 2:34 PM EDT, Sep 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Teva Announces Launch of Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗
Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company... 
Via MarketBeat
News headline image
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva (TEVA) Q2 2026 Earnings Call Transcript ↗
Key innovative brands now generate over $1B quarterly revenue. 
Via The Motley Fool
Topics Earnings
News headline image
Why Teva Pharmaceutical Stock Surged This Week ↗
Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst. 
Via The Motley Fool
Topics Stocks
News headline image
Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗
Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were... 
Via MarketBeat
Topics Earnings
News headline image
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗
The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline. 
Via The Motley Fool
News headline image
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗
The stock has a 100% buy rating from polled analysts, with some eye-catching price targets. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the... 
Via MarketBeat
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability? 
Via The Motley Fool
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Polpharma Biologics International AG
Via Business Wire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. 
Via The Motley Fool
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum. 
Via The Motley Fool
News headline image
Teva Releases Q2 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
Driving revenue growth and earnings growth are two different things. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.